Companies are starting to bet big on psychedelic drugs to treat US mental health epidemic
Once dismissed as a "party drug" for its hallucinogenic effects, ketamine is emerging as a novel...
Taking the active ingredients of psychedelics and proving their effectiveness in the clinic...
Set up two years ago, it has attracted more than US$100mln in Series A and B funding that has...
The New York clinical-stage biopharmaceutical company has several drugs in the pipeline capable...
Portfolio includes blockchain firm Arcology, Pressland, which is dedicated to fighting fake...
Albert Labs Chief Medical Officer Dr. Malcom Barratt-Johnson joined Steve Darling from Proactive to share details about the private company with a focus on the emerging field of psychedelic-assisted therapy and research. Dr. Barratt-Johnson talks about the origins of Albert Labs and about their...
